当前位置:首页 > 关于我们 > 创投导师 > 衷兴华

衷兴华 | Zhong Xinghua


39.jpg

衷兴华


肝胆外科医生  

曾任中国某三甲医院院长,并在法国Poitiers 大学学习MBA,在法国POITIERS大学医院担任院长助理(实习),学习法国医院管理。

曾任在中国华源集团和多个医药企业担任高级管理人员。

曾凭其对医药技术和临床应用前景的理解,成功投资过中国A股创业版和科创版多个TOP公司,获得丰厚回报。

衷兴华医生长期追踪研究全球肿瘤医疗新技术和新进展,曾参加中国首个质子重粒子放疗中心的项目引进论证工作,深入实地考察和研究过全球主要的粒子放疗中心。

曾作为专业顾问,发起和帮助中国著名投资基金鼎晖投资(CDH)和远大医药集团并购澳大利亚的SIRTEX公司,并把钇90核素治疗肝癌技术引进到中国。

 现专注于研究肿瘤微创消融等相关新技术研发和推广,试图用工程化的手段创新实体肿瘤局部解决方案,致力于推广和传播:“局部治疗+化疗和免疫”治疗恶性肿瘤的新技术和新方案,帮助更多癌症患者找到好医生和好技术。


Zhong Xinghua

Hepatobiliary Surgeon | MBA, University of Poitiers, France

Experienced hepatobiliary surgeon with senior leadership experience in China’s Tertiary(Class-A) Hospital in China hospital system. Completed an MBA at the University of Poitiers and served as Assistant to the CEO (internship) at the University Hospital of Poitiers, gaining hands-on exposure to the French hospital management model.

Held senior management positions within China Huayuan Group and several pharmaceutical companies, overseeing strategic planning, business operations, and commercialization initiatives.

Leveraging deep insight into medical technologies and clinical application trends, achieved successful investments in several top-performing companies listed on China’s ChiNext and STAR Market, delivering substantial returns.

Dr. Zhong Xinghua has long pursued emerging technologies and global innovations in oncology. He participated in the technology assessment and introduction of China’s first Proton and Heavy-Ion Therapy Center and conducted extensive field studies at major particle therapy centers worldwide.

As a specialist consultant, he initiated and supported the acquisition of Australia’s Sirtex by CDH Investments and Grand Pharmaceutical Group, facilitating the introduction of Y-90 radioisotope therapy for liver cancer into China.

Currently focused on advancing minimally invasive ablation and other next-generation oncology technologies, with a mission to engineer innovative local treatment solutions for solid tumors. Dedicated to promoting integrated approaches that combine local therapy + chemotherapy + immunotherapy, and committed to helping cancer patients access the best clinicians and technologies available.


0.193277s